Related Experiment Videos
Small hepatocellular carcinoma: current status and prospects
1Liver Cancer Institute & Zhongshan Hospital, Fudan University, Shanghai 200032, China. zytang@srcap.stc.sh.cn
Hepatobiliary & Pancreatic Diseases International : HBPD INT
|November 11, 2003
Summary
Surgical resection for small hepatocellular carcinoma (HCC) has improved patient outcomes. Advances in surgical techniques have increased resectability and survival rates, making it the primary treatment for HCC with compensated liver function.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Gastroenterology
Background:
- Hepatocellular carcinoma (HCC) treatment has evolved significantly over the past decades.
- Early reports of surgical resection for small HCC demonstrated improved patient prognoses.
Purpose of the Study:
- To review historical and recent data on surgical resection for small HCC.
- To prospect future trends in managing small HCC.
Main Methods:
- Analysis of 1232 patients with small HCC treated between 1960 and 1999.
- Review of literature and data from the Liver Cancer Institute of Fudan University.
Main Results:
- Surgical resection rates increased from 76.6% to 95.5% between 1960-1984 and 1985-1999.
- Operative mortality decreased from 2.4% to 1.2%, and 5-year survival improved from 53.1% to 64.0%.
- Limited resection showed higher 5-year survival (64.4%) than lobectomy (55.9%) and was superior to other regional therapies (32.8%).
Conclusions:
- Surgical resection is the preferred treatment for small HCC in patients with compensated liver function.
- Regional therapies and liver transplantation are alternatives for patients with decompensated liver function.
- Tumor biology remains a critical factor influencing small HCC prognosis.